Enoxaparin is safe for the treatment of venous thromboembolisms in patients with renal dysfunction: A retrospective cohort study

Unfractionated heparin (UFH) and low molecular weight heparins (LMWH), such as enoxaparin, are commonly used anticoagulants for the prevention and treatment of venous thromboembolisms. Several studies have compared their safety and efficacy, including a meta-analysis that showed them to be similarly efficacious with no difference in bleeding risk [1]. While UFH has been used in practice longer, LMWH offers a more predictable pharmacokinetic profile and requires less laboratory monitoring.
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research